Bristol Myers Squibb has successfully completed the acquisition of Karuna Therapeutics, Inc. This acquisition adds KarXT, an antipsychotic with a novel mechanism of action, and Karuna’s early-stage and pre-clinical pipeline to Bristol Myers Squibb’s portfolio, reinforcing its commitment to strengthening its growth profile in the latter half of the decade and beyond.